Considerations for the Design and Operation of Cross-Border Early-Phase Clinical Trials

As pharmaceutical innovation in China accelerates, more companies are expanding into global development. Cross-border early-phase clinical trials have become a critical pathway in global drug development.

From proof of concept (POC) to simultaneous global development, clinical trial design and operation are no longer purely technical challenges. They now require strategic planning, regulatory alignment, data integration, and risk management.

The Strategic Transformation of Early-Phase Development

As shared by Dr. Lingshi Tan, Executive Chairman of Caidya, three key trends are shaping early-phase development.

First, POC requires strategic alignment. It is no longer just a step to validate efficacy signals, but a key decision point influencing an asset’s development path. Study design should align with long-term registration strategy, target population, and resource allocation.

Second, regulatory engagement must be integrated early to improve continuity and predictability.

Third, data integration has become a key indicator of development maturity. Modern programs involve biomarkers, multi-omics, and digital data, requiring strong integration capabilities.

Regulatory Pathways and MRCT Planning

Successful multi-regional clinical trials (MRCTs) require understanding key ICH guidelines (E6, E17, E5, M3(R2)) and anticipating expectations from major regulators including the US FDA, EMA, and China’s NMPA.

Planning should begin before IND submission, integrating requirements from key markets early to avoid delays.

The US FDA continues to emphasize patient population representativeness. In the EU, the Clinical Trial Information System (CTIS) enables a “single submission, multiple-country review” process, improving efficiency.

Statistical Considerations and Regional Differences

Within the ICH E17 framework, MRCT design should address consistency evaluation, sample size allocation, and regional stratification.

Sample size strategies should balance proportional and equal allocation, with regional requirements confirmed through early regulatory engagement.

While “one protocol, globally applicable” remains the goal, designs must allow flexibility for regional differences in clinical practice, comparators, and patient populations. Early feasibility assessments are essential to ensure both scientific rigor and operational feasibility.

Practical Considerations: Going Global and Entering China

Conducting Clinical Trials Outside China (“Going Global”)

Before initiating trials overseas, sponsors should define budget, timeline, target countries, study design (MRCT vs. standalone), sample size allocation, dose strategy, and testing locations.

Common challenges include startup delays, protocol amendments, vendor changes, and site activation timelines. These should be addressed through proactive planning.

Differences between China and the US in startup processes, site selection, cost structures, and monitoring require tailored approaches.

Bringing Overseas Assets to China

China has undergone significant regulatory reform, reducing IND review timelines to 60 working days, with accelerated pathways of 30 days for eligible therapies.

China is largely aligned with ICH standards, and in many cases additional studies are no longer required (with some CMC exceptions for large molecules).

Investigator-initiated trials (IITs) are increasingly used for early proof of concept, especially in cell and gene therapy. While faster and more flexible, they differ from traditional IND pathways in structure and oversight.

Data Compliance and Sample Management

China’s data privacy framework imposes strict requirements on cross-border transfer of sensitive data, including health information.

HGRAC regulations also require approval or filing for biological sample export, which must be planned early.

Globally, compliance with HIPAA (US) and GDPR (EU) is required. Sample export rules vary, with stricter controls in China and more streamlined processes in the US and EU for non-infectious samples.

Timeline, Cost, and Quality Management

Timelines are often affected by startup delays, enrollment challenges, protocol amendments, and database lock timing. Strategic site selection and preparation are key.

Cost management requires structured budgeting, contingency planning, and ongoing tracking.

Quality management is increasingly driven by RBQM and quality by design. Identifying critical-to-quality factors and combining monitoring approaches helps ensure patient safety and data integrity.

Conclusion

Cross-border early-phase trials are shifting from execution-focused to strategy-driven. Success depends on early regulatory planning, strong operations, flexibility across regions, and integrated data and risk management.

Balancing global strategy with local execution is essential for successful global drug development.